Health Economics›Glioblastoma›First-line therapy standard patients

First-line therapy standard patients

Glioblastoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Concurrent Bevacizumab and RT, then Irinotecan and Bevacizumab maintenance Variant #01	—	R 96 316	56d	—	—	~2	~R 116 303 indirect	—
Temozolomide and RT Variant #01	—	R 19 131	45d	7.9 mo	18.7 mo	12	R 59 601 PFS proxy	7
Lomustine, Temozolomide, RT Variant #01 Partial	—	R 2 453	42d	—	48.1 mo	6	R 14 716 PFS proxy	1
PCV Variant #02 Partial	—	R 327	56d	—	~57.6 mo	~6	~R 1 959 PFS proxy · indirect	3
Radiation therapy N/A - radiation	—	—	49d	—	7.5 mo	—	—	7
RT, then Carmustine Variant #01 Partial	—	—	49d	—	—	~1	—	—
Nimustine and RT Variant #01 Partial	—	—	—	—	27.4 mo	1	—	—
Carmustine and RT Variant #01 Partial	—	—	42d	—	10.6 mo	7	—	1

8 of 8 regimens shown